Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10158418 | Clinical Therapeutics | 2018 | 8 Pages |
Abstract
Inhalation of nemiralisib was well tolerated in these healthy subjects. Plasma pharmacokinetic variables were well defined, and charcoal block data indicate that â¼23% of the total systemic exposure after inhalation from Ellipta was attributable to orally absorbed drug. ClinicalTrials.gov identifier: NCT02691325.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Robert BSc, Emily MSc, Mickael PhD, J. Nicole DPhil, Edith M. PhD, Anthony MBBS, PhD,